caprolactam has been researched along with Abdominal Migraine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burgey, CS; Deng, JZ; Kane, SA; Mosser, SD; Nguyen, DN; Paone, DV; Potteiger, CM; Roller, S; Salvatore, CA; Selnick, HG; Shaw, AW; Vacca, JP; Williams, TM; Yu, S | 1 |
| Burgey, CS; Graham, SL; Kane, SA; Koblan, KS; Mosser, SD; Nguyen, DN; Paone, DV; Rutledge, RZ; Salvatore, CA; Shaw, AW; Stump, CA; Vacca, JP; Williams, TM | 1 |
2 other study(ies) available for caprolactam and Abdominal Migraine
| Article | Year |
|---|---|
Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: discovery of MK-2918.
Topics: Analgesics, Non-Narcotic; Animals; Azepines; Biological Availability; Calcitonin Gene-Related Peptide Receptor Antagonists; Caprolactam; Cells, Cultured; Dogs; Humans; Imidazoles; Inhibitory Concentration 50; Macaca mulatta; Migraine Disorders; Molecular Structure; Rats; Structure-Activity Relationship | 2011 |
Caprolactams as potent CGRP receptor antagonists for the treatment of migraine.
Topics: Administration, Oral; Animals; Calcitonin Gene-Related Peptide Receptor Antagonists; Caprolactam; Chemistry, Pharmaceutical; Drug Design; Humans; Imidazoles; Inhibitory Concentration 50; Kinetics; Migraine Disorders; Models, Chemical; Rats | 2007 |